Melanoma during fingolimod treatment for multiple sclerosis

Eur J Cancer. 2019 May:113:75-77. doi: 10.1016/j.ejca.2019.03.011. Epub 2019 Apr 12.
No abstract available

Keywords: Adverse effect; FTY720; Fingolimod; Melanoma; Multiple sclerosis; Side effect.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Back
  • Female
  • Fingolimod Hydrochloride / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunosuppressive Agents / therapeutic use*
  • Melanoma / diagnosis*
  • Melanoma / immunology
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Natalizumab / therapeutic use
  • Risk Factors
  • Skin Neoplasms / diagnosis*
  • Skin Neoplasms / immunology

Substances

  • Immunologic Factors
  • Immunosuppressive Agents
  • Natalizumab
  • Fingolimod Hydrochloride